- Sivick K.E., Mobley H.L.T. Waging war against uropathogenic escherichia coli: Winning back the urinary tract. Infect. Immun. 2010;78:568–585. doi: 10.1128/IAI.01000-09
- Baron E.J., Miller J.M., Weinstein M.P., Richter S.S., Gilligan P.H., Thomson R.B., Bourbeau P., Carroll K.C., Kehl S.C., Dunne W.M., et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) a. Clin. Infect. Dis. 2013;57:22–121. doi: 10.1093/cid/cit278.
- Luís Â., Domingues F., Pereira L. Can cranberries contribute to reduce the incidence of urinary tract infections? A systematic review with meta-analysis and trial sequential analysis of clinical trials. J. Urol. 2017;198:614–621. doi: 10.1016/j.juro.2017.03.078.
- Spaulding C., Hultgren S. Adhesive pili in UTI pathogenesis and drug development. Pathogens. 2016;5:30. doi: 10.3390/pathogens5010030.
- Lane M.C., Mobley H.L.T. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int. 2007;72:19–25. doi: 10.1038/sj.ki.5002230.
- Scholes D., Hooton T.M., Roberts P.L., Gupta K., Stapleton A.E., Stamm W.E. Risk factors associated with acute pyelonephritis in healthy women. Ann. Intern. Med. 2005;142:20. doi: 10.7326/0003-4819-142-1-200501040-00008
- Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015;13:269–284. doi: 10.1038/nrmicro3432.
- Tamadonfar K.O., Omattage N.S., Spaulding C.N., Hultgren S.J. Reaching the end of the line: Urinary tract infections. Microbiol. Spectr. 2019;7:1–16.
- Nik-Ahd F., Lenore Ackerman A., Anger J. Recurrent urinary tract infections in females and the overlap with overactive bladder. Curr. Urol. Rep. 2018;19:94. doi: 10.1007/s11934-018-0839-3.
- Beerepoot M., Geerlings S. Non-antibiotic prophylaxis for urinary tract infections. Pathogens. 2016;5:36. doi: 10.3390/pathogens5020036
- Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Care Res. 2001;45:101–106. doi: 10.1002/1529-0131(200102)45:1<101::AID-ANR90>3.0.CO;2-7.
- Sartor RB. Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther. 1997;11(suppl 3):17–22
- Malin M, Verronen P, Korhonen H, Syväoja EL, Salminen S, Mykkänen H, Arvilommi H, Eerola E, Isolauri E. Dietary therapy with Lactobacillus GG, bovine colostrum or bovine immune colostrum in patients with juvenile chronic arthritis: Evaluation of effect on gut defence mechanisms. Inflammopharmacology. 1997;5:219–236. doi: 10.1007/s10787-997-0001-1.
- So JS, Kwon HK, Lee CG, Yi HJ, Park JA, Lim SY, Hwang KC, Jeon YH, Im SH. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol. 2008;45:690–699. doi: 10.1016/j.molimm.2007.07.006.
- Rodriguez-Cabezas ME, Fisac F, Bailon E, Comalada M, Camuesco D, Xaus J, Concha A, Talavera P, Nieto A, Zarzuelo A, Galvez J. Lactobacillus fermentum exerts a beneficial effect in an experimental model of rheumatoid arthritis in mice. Proc Nutr Soc. 2008;67:E66. doi: 10.1017/S0029665108006757.
- Kano H, Kaneko T, Kaminogawa S. Oral intake of Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 prevents collagen-induced arthritis in mice. J Food Prot. 2002;65:153–160.
- Kato I, Endo-Tanaka K, Yokokura T. Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice. Life Sci. 1998;63:635–644. doi: 10.1016/S0024-3205(98)00315-4.
- Broek MF van den, van Bruggen MC, Kiipman JP, Hazenberg MP, Berg WB van den. Gut flora induces and maintains resistance against streptococcal cell wall-induced arthritis in F344 rates. Clin Exp Immunol. 1992;88:313–317.
Recenzije
Još nema recenzija.